BrainCool (BRAIN.ST) Stock Analysis & AI Equity Report
BrainCool (BRAIN.ST) overview
BrainCool (BRAIN.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, BrainCool reported revenue of SEK 40.0m and operating profit of SEK -42.2m; the year-end share price was 1.37 SEK and market capitalisation was SEK 347m. BrainCool is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BrainCool's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About BrainCool
BrainCool AB (publ) develops and markets medical cooling systems for targeted temperature management and cryotherapy. Its products include the BrainCool System, used for controlled patient cooling, RhinoChill for rapid pre-hospital cooling, and Cooral for reducing chemotherapy-induced oral mucositis. The company serves stroke, cardiac arrest and oncology care settings.
Generate the BrainCool report
BrainCool is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BrainCool and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.